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I. INTRODUCTION 
Carcinoid heart disease in human is a rare condition that occurs as a  part of 
carcinoid syndrome, a systemic disorder mediated by elevated circulating levels of 
vasoactive substances, including serotonin, histamine, bradykinin, tachykinins 
produced by a rare metastatic neuroendocrine malignancy carcinoid. 
Carcinoid syndrome is characterized by a triad of symptoms such as flushing, 
diarrhoea and bronchospasm that occur in association with hepatic metastases.  High 
level of vasoactive substance, particularly 5 HT in the right side of the heart causes 
progressive fibrotic endocardial plaque. Features of thickened immobile tricuspid and 
pulmonary valves with stenosis and regurgitant lesions are highly suggestive of 
carcinoid heart disease. It manifests as right heart failure. 
Elevation of urinary 5 Hydroxy Indole Acetic Acid (5 – HIAA) levels is 
highly specific and moderately sensitive for diagnosis of carcinoid syndrome and it is 
confirmed by echocardiography  and cardiac MRI1. 
Serotonergic drugs cause valvular fibrosis similar to that seen in patients with  
carcinoid heart disease. 
In animals serotonin produced cardiac changes as that of human carcinoid  
heart disease. The free fraction of serotonin in blood is probably the biologically 
active substance causing   carcinoid syndrome and carcinoid heart disease2. 
In rats exposed to long term administration of serotonin, increased cell 
proliferation and thickening of the heart valves that resembles the changes reported in 
patients with carcinoid heart disease are observed. Serotonin increases cell 
INTRODUCTION 
Institute of Pharmacology, MMC.  Page | 2 
 
proliferation in several cell types, including valvular interstitial cells and vascular 
smooth muscle cells. 
There is evidence for activation and nuclear translation of mitogen- activated 
protein kinases and other proliferative pathways by serotonin. Rective oxygen species, 
especially superoxide (O2), appear to participate in serotonin induced mitogenesis. 
Antioxidants   has been found to prevent the mitogenic effects of serotonin3. 
The herbal drugs have been used throughout the world and have raised greater 
attention in recent times, because of their diverse nature of curing disease, safety and 
high level of tolerance compared to conventional medicine4. Red reishi mushroom          
(Ganoderma lucidum) has been used in traditional Chinese medicine for more than 
4000 years5. 
It has been known to have numerous pharmacological effects including 
immune modulating, anti- inflammatory, anti cancer, anti diabetic effect. It inhibits 
mitogen protein kinase enzyme, increases anti – oxidative enzyme activity and 
exhibits direct free radical scavenging activity. 
It has been found to be effective in coronary heart disease, chronic bronchitis, 
hypertension. In addition to its diuretic and ACE inhibitory effect, the cardiac 
protective activity  by reducing lipid peroxidation has also been established6. 
No scientific studies have been carried out so far to evaluate its effect on 
carcinoid heart disease. Hence the present study to evaluate the effect of Ganoderma 
lucidum on inhibiting serotonin induced carcinoid heart disease by its antioxidant 
property has been attempted. 
DISEASE PROFILE 
Institute of Pharmacology, MMC.  Page | 3 
 
II. DISEASE PROFILE: 
Carcinoid heart disease (CHD, Hedinger syndrome), an unique manifestation, 
has been described in up to 60% of patients with both Neuro Endocrine Tumors and 
Carcinoid Syndrome, typically inducing abnormalities of the right side of the heart .  
CHD occurs most frequently in patients with Neuro Endocrine Tumors 
originating in the small bowel (72%) followed by NETs of the lung, large bowel, 
pancreas, appendix,  ovarian origin and gonads7. 
Nearly 50% of patients exhibiting the carcinoid syndrome will develop 
carcinoid heart disease (CHD) with fibrotic endocardial plaques and associated heart 
valve dysfunction that classically involves the tricuspid valve. Advanced changes of 
tricuspid valvular disease rather than tumor dissemination, is the cause of death in 
approximately one-third of these patients8.  
Serotonin is presumed to be the catalyst for the cardiac fibrotic process. 
Nearly 95% of patients present with right-sided heart valve disease, characterized by 
tricuspid insufficiency and pulmonary stenosis and the subsequent development of 
pulmonary hypertension. Left-sided cardiac disease may be seen in up to 10% of 
patients, and is commonly associated with angina and coronary vasospasm9. 
 
 
 
 
 
DISEASE PROFILE 
Institute of Pharmacology, MMC.  Page | 4 
 
  PATHOPHYSIOLOGY:  
Carcinoid heart disease is characterized by thickening of the tricuspid and 
pulmonary valves result in regurgitation and /or stenosis of the affected valves. Any 
or all of the cardiac valves can be affected, with tricuspid regurgitation being the most 
frequently observed pathology. 
The characteristic pathological findings are endocardial plaques of fibrous 
tissue that may involve the tricuspid valve, pulmonary valve, cardiac chambers, vena 
cava, pulmonary artery, and coronary sinus. The fibrous reaction may involve not 
only the valve leaflets, but also the subvalvular apparatus including the tendinous 
chords and papillary muscles of the tricuspid valve, and more rarely the mitral valve 
in cases with left sided involvement.  
The fibrous tissue in the plaques results in distortion of the valves leading to 
either stenosis, regurgitation, or both. The preferential right heart involvement is most 
likely related to inactivation of the vasoactive substances by the lungs. In the 5–10% 
of cases with left sided valvular pathology, one should suspect either  extensive liver 
metastases, bronchial carcinoid, or a patent foramen ovale10,11. 
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 Fig: 1 Fig: 2 
The precise mechanisms responsible for the development of CHD remain 
obscure. The disease is thought to be multifactorial and mediated by a variety of 
vasoactive substances secreted by the tumor, including 5-HT (serotonin), 
prostaglandins, histamine, bradykinin, and other substances with fibroblast 
proliferative properties such as tachykinins (substance P, neurokinin A, neuropeptide 
K) or transforming growth factor-β (TGF-β), which finally lead to the deposition of 
plaques on the endocardial surfaces of valve leaflets, subvalvular apparatus (chordae 
and papillary muscles) and cardiac chambers and occasionally within the intima of the 
pulmonary arteries and the aorta. 
These plaque-like deposits are composed of myofibroblasts, smooth muscle 
cells, extracellular matrix (ECM) components (collagen and myxoid ground 
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substance), and an endocardial cell layer. These deposits usually involve primarily the 
right side of the heart (in ∼90% of cases), specifically the downstream side of the 
valve leaflets, i.e. the ventricular aspect of the tricuspid valve and the pulmonary 
arterial side of the pulmonary valve .  
                           
 
                                                Fig: 3 Enlarged right ventricle 
Simultaneous involvement of both the tricuspid and pulmonary valves 
strongly suggests CHD as the likely diagnosis, demonstrating a pathognomonic 
appearance. In the pulmonary valve the plaques are deposited on the leaflets, leading 
to the adherence of pulmonic leaflets to the pulmonary arterial endocardium and 
resulting in a mixture of valvular stenosis and regurgitation, whereas in the tricuspid 
valve regurgitation tends to be predominant as the plaques involve mainly the 
subvalvular apparatus12. 
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The complex mechanism of cardiac plaque formation in CHD is considered to 
be multifactorial. Initial animal studies postulated that the variety of vasoactive 
substances secreted by the NET may exert paraneoplastic effects. For example, 
bradykinin has been reported to induce endocardial injury, the resulting fibrosis 
representing a healing response of the endocardium. Moreover, tachykinin was 
described as a pro-proliferative agent for the endocardial fibroblasts, thereby inducing 
plaque formation.  
Nowadays, there is a strong body of evidence implying that serotonin plays a 
major role in stimulating fibroblast growth and fibrogenesis. It is well known that 
urinary 5-hydroxyindoleacetic acid (5-HIAA), the serotonin metabolite which reflects 
the amount of serotonin production, is significantly higher in patients with CHD 
compared with those without cardiac involvement12,10.  
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THE SIGNAL TRANSDUCTION EFFECTS INDUCED BY THE 5-
HT2B RECEPTOR ACTIVATION IN DIFFERENT CELLS AND TISSUES 
ARE COMPLEX AND MAY INCLUDE THE FOLLOWING: 
 Stimulation of phospholipase C and phospholipase A2 . 
  Stimulation of nitric oxide synthase. 
 Mitosis initiation  together with the increase in the secretion of 
inflammatory cytokines such as TNF-α and ECM components . 
 Activation of MAPK (mitogen-activated protein kinase). Phosphorylation 
of the cytoplasmic tyrosine kinase Src and activation of ERK 
(extracellular-regulated kinase) . 
  Phosphorylation of retinoblastoma protein (Rb-P) and cell cycle 
progression. 
  Over expression of TGF-β1: the 5-HT2B receptor works in concert with 
the angiotensin II type 1 receptor (AT1R) to mediate hypertrophic 
signalling in cardiac fibroblasts. The agonist signalling of these receptors 
has been shown to induce an increase in the synthesis and up regulation of 
the cytokine TGF-β1, known to stimulate fibroblasts to produce ECM 
proteins; TGF-β1 is over expressed in CHD lesions and seems to be a 
major mediator in the tissue changes related to the valvular disease. 
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The signal transduction effects  induced by the 5-HT2B receptor activation. PDGF = 
Platelet-derived growth factor; EGF = epidermal growth factor; Rb-P = 
phosphorylation of retinoblastoma protein12.                                
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DIAGNOSIS: 
The key investigations for the diagnosis of carcinoid heart disease  is 
transthoracic echocardiography13,14,15. 
Basic screening  with a 12 lead ECG. Between 30–50% of ECGs are normal; 
non-specific ST segment changes and sinus tachycardia are the most common 
abnormal findings and p pulmonale or right bundle branch block may also be seen on 
occasion . 
TREATMENT:           
Patients with cardiac involvement tend to have higher circulating 
concentrations of 5-HIAA and more advanced disease. The principles of management 
of patients with carcinoid heart disease can be divided into the treatment of right heart 
failure, pharmacotherapy to reduce the secretion of tumour products, and 
surgical/interventional treatment of valvar pathology. 
HEART FAILURE MANAGEMENT 
 Right heart failure can be successfully treated with a combination of loop 
diuretics and digoxin. Often, loop diuretics alone are enough to achieve 
sufficient fluid loss, but if additional diuresis is required, the judicious 
coadministration of a thiazide diuretic usually produces the desired effect. 
  Digoxin is believed to help with right ventricular contractility although the 
data on pure right sided heart failure(without concomitant lung disease or 
pulmonary hypertension) are confirmed 12,13.  
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III. DRUG PROFILE: 
 
 Fig 5  Fig:6    Pure Red Reishi Mushroom 
Kingdom:    Fungi 
Division:     Basidiomycota 
Class:          Agaricomycetes 
 Order:Polyporales  
 Family:Ganodermataceae  
 Genus:Ganoderma  
 Species: Ganoderma lucidum(Curtis)P. Karst  
 Official Latin Name: Ganoderma lucidum , 
 Biological Scientific Name:Ganoderma lucidum.16,6  
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 COMMON NAMES 
United States:     Reishi mushroom (Herbs of Commerce), Ganoderma. 
China:                Ling zhi, ling zhi cao, ling chih, hong lingzhi, chi zhi (Ganoderma 
lucidum);                                                                                                                               
he ling zhi, zi zhi (Ganoderma japonicum) (Mandarin). 
Japan:                Reishi, mannentake; rokkaku reishi (antler form). 
Korea:                Young ji. 
Vietnam:            Ling chi17. 
 
Botanical Source:  The fruiting body of Ganoderma lucidum (Leyss. ex Fr.) Karst. 
 Parts  Used:  The  fruiting body of the mushroom . 
Harvest and Processing:  
      Collect fruiting bodies in autumn; remove soil, sand and other foreign matter; dry 
in shaded areas or under the sun.  
 
Fig 7 
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Distribution: 
              Reishi mushrooms grows wild on decaying logs and tree stumps in the 
coastal provinces of China. It occurs in six different colours, but the red variety is 
most commonly used and commercially cultivated in north America, China, 
Taiwan17,18.        
                The reishi mushroom is a purplish-brown fungus with long stalk, brown 
spores, and a fan-shaped cap with a shiny, varnish-coated appearance, Reishi grow  on 
decaying wood or tree stumps, preferring the Japanese plum tree and found on oak. 
Cultivation of reishi is long, complicated process. 
The reishi grows in 6 colors,each thought to have different charaterstics and known as 
 Aoshiba (blue reishi)                
  Akashiba (red reishi), 
 Kishiba (yellow reishi), 
  Shiroshiba (white reishi), 
 ,Kuroshiba (black reishi),  
  Murasakishiba (purple reishi). 
Active constituents: 
                  Ganoderma lucidum produces a group of triterpenes, called ganoderic 
acids, which have a molecular structure similar to steroid hormones.  It also  
contains other compounds often found in fungal materials, 
including polysaccharides (such as beta- Lucan), coumarin, mannitol,  
canthaxanthin, lanostan and alkaloids. Sterols isolated from the mushroom 
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include  ganoderol, ganoderenic acid,  ganoderiol, ganodermanontriol, lucidadiol, 
and ganodermadiol6. 
THERAPEUTIC USE: 
Immunopotentiator: 
Lingzhi accelerates the production of interlukin-2 from helper T cells and 
potentiates the induction of different types of anti-tumor cells, such as NK cells and 
cytotoxic macrophages, in addition to the induction of interferon production. 
It stimulates the immune system to activate both B-lymphocytes and T-
lymphocytes natural T- killer cells, improving immune surveillance. It can be 
effective againt food allergies and is valuable in the treatment of  Epstein –Barr virus 
infection. 
Cancer: 
Anticancer effects of reishi have been reported largely from in vivo 
experiments, and data from clinical trials have been published. It is generally accepted 
that the anticancer effects are due to immune enhancement , and may be exhibited 
from diverse chemical constituents in reishi.   
Cardiovascular effects: 
                   Red reishi Mushroom (Ling Zhi) helps to promote the function of the 
heart. The effect of reishi on the cardiovascular system has been investigated. 
Regulation of high blood pressure were reported to be attributed to the ganoderic 
acids.  Angiotensin-converting enzyme-inhibiting triterpenes from reishi have been 
described.  Inhibition of cholesterol biosynthesis, enhanced antioxidase activity, 
decreased platelet aggregation,  and reduced lipid peroxidation have been 
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demonstrated in animal and in vitro experiments.  It is also found to be useful in 
congestive heart failure. 
 
Diabetes: 
           In animal experiments, ganopoly affected carbohydrate metabolism and 
promoted insulin secretion. In a clinical trial of patients with type 2 diabetes, 
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ganopoly 1,800 mg 3 times daily reduced postprandial glucose values. The glucans 
ganoderan A and B (glucans) inhibited hyperglycemia in clinical studies16,18.   
Hepatitis: 
       In vitro and in vivo animal experiments, hepatoprotection by extracts of 
ganoderma against induced liver damage has been demonstrated.  Polysaccharide 
ganopoly therapy for 6 months resulted in normalization of aminotransferase levels in 
33% and cleared serum hepatitis B surface antigen in 13% of trial participants 
compared with control.   
Rheumatoid Arthritis: 
                 The effect of reishi on the immune system has been studied   in vitro 
experiments. In an experiment using synovial fluid from patients with rheumatoid 
arthritis, researchers demonstrated an inhibitory effect of a polysaccharide extract on 
the proliferation of synovial fibroblasts, possibly via the nuclear factor-kappa B 
transcription pathway.  Two clinical trials have been conducted involving patients 
with rheumatoid arthritis. Both trials used a combination of lingzhi plus San-Miao-
San, therefore making it difficult to attribute the positive outcomes to the individual 
agents.   
Antiviral effects: 
Polysaccharides isolated from reishi have been proven effective in vitro 
against herpes simplex virus types 1 and 2.  Reishi isolates also have been tested 
against other viral strains, including influenza A, and demonstrated effectiveness 
against their replication.   
Contraindications: 
Contra indications have not been identified . 
Pregnancy/Lactation: 
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Information regarding safety and efficacy in pregnancy and lactation is lacking. 
Interactions:   None well documented19,20. 
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IV. REVIEW OF LITERATURE: 
1. Rebecca Dobson et al (2015) reported the Association of a Panel of 
Biomarkers with the presence and severity of carcinoid Heart Disease: A 
cross-sectional study of patients with neuro endocrine tumours with 
documented liver metastases and/or carcinoid syndrome. Serum was 
analyzed for Chromogranin A, Chromogranin B and N-terminal pro Brain 
Natriuritic Peptide (NT-proBNP). Plasma was analyzed for Neurokinin A and 
5-Hydroxyindoleacetic acid (5HIAA). Echocardiography was used to 
determine the presence and severity of carcinoid heart disease. NT-proBNP 
and plasma 5HIAA are both sensitive and specific biomarkers for the 
presence of carcinoid heart disease whereas only NT-proBNP is moderately 
correlated with disease severity21. 
 
2. Wiebke Janssen et al  ( 2015)  5-HT2B Receptor Antagonists Inhibit Fibrosis 
and Protect from RV Heart Failure. To investigate the effects of Terguride 
(5-HT2A and 2B receptor antagonist) or SB204741 (5-HT2B receptor 
antagonist) on right heart function and structure upon pulmonary artery 
banding (PAB) in mice. Methods. Seven days after PAB, mice were treated 
for 14 days with Terguride (0.2 mg/kg bid) or SB204741 (5mg/kg day). 
Right heart function and remodeling were assessed by right heart 
catheterization, magnetic resonance imaging (MRI), and histomorphometric 
methods. Chronic treatment with Terguride or SB204741 reduced right 
ventricular fibrosis and showed improved heart function in mice after PAB22. 
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3. Buda A et al (2012) reported the Primary insular carcinoid of the ovary with 
carcinoid heart disease:  High level of 5-HIAA has a rule in 
the development and progression of the carcinoid heart syndrome and could 
lead the right tricuspid valvular involvement23. 
4.   Alexandra KeKewska et al (2012) reported the antiserotonergic properties 
of terguride in Blood vessels, Platelets, and valvular Interstitial cells.  Kinetic 
studies on the effects of terguride in pulmonary arteries showed that the rate 
to reach drug-receptor equilibrium for terguride was fast. Pretreatment with 
terguride inhibited 5-HT-induced amplification of ADP-stimulated human 
platelet aggregation (IC50 16 nM). In porcine valvular interstitial cells, 5-HT-
induced activation of extracellular signal-regulated kinase (ERK) 1/2, an 
initiator of cellular proliferation and activity, was blocked by terguride as 
shown by Western blotting24. 
5. Silva scott R et al (2011) reported the Effect of PTEN on Serotonin Synthesis 
and Secretion from the Carcinoid Cell Line BON. PTEN was inhibited by 
pharmacological and molecular approaches, and the resultant secretion of 
serotonin and expression of tryptophan hydroxylase (TPH1), the rate-limiting 
enzyme in serotonin synthesis, was assessed. Inhibition of PTEN in vitro, 
with concomitant increased Akt signaling, resulted in decreased secretion of 
serotonin, as well as decreased serotonin synthesis, as confirmed by reduced 
expression of TPH1. Inhibition of PTEN in BON cells in an animal model 
resulted in decreased serum serotonin.  By inhibiting signaling through Akt, 
PTEN indirectly promotes serotonin synthesis and secretion26. 
6. Droogmans et al (2009) reported the Cyproheptadine prevents pergolide - 
induced valvulopathy in rats, Echocardiographic and histopathological 
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study. 50 male Wistar rats received daily intraperitoneal injections of 
pergolide (0.5 mg/kg, n = 14), pergolide (0.5 mg/kg) combined with 
cyproheptadine (10 mg/kg, n = 12), cyproheptadine (10 mg/kg, n = 12), or no 
injections (control, n = 12) for 20 wk. Echocardiography was performed 
blindly at baseline and at 10 and 20 wk followed by pathology. At baseline, 
no differences between groups were found with echocardiography. At 20 wk, 
aortic regurgitation was present in all pergolide-treated animals, whereas it 
was less frequently observed in the other groups (P < 0.0001). For 
the other valves, this difference was less pronounced. On histopathology, not 
only aortic but also mitral valves were thicker, myxoid, and exhibited more 
5-HT(2B)R-positive cells in pergolide-treated animals compared with 
the other groups27.  
7. Ricardo. A et al (2009) reported the Serotonin produces monoamine oxidase-
dependent oxidative stress in human heart valves.  serotonin induces 
oxidative stress in human heart valves, and examined mechanisms by which 
serotonin may increase reactive oxygen species. Superoxide (O2·−) was 
measured in heart valves from explanted human hearts that were not used for 
transplantation. O2·− levels (lucigenin -enhanced chemo luminescence) were 
increased in homogenates of cardiac valves and blood vessels after 
incubation with serotonin28. 
8. Rajamannan NM et al (2007)  reported the Cell proliferation in carcinoid 
valve disease: a mechanism for serotonin effects. Serotonin is a powerful 
mitogen for valvular subendocardial cells. The mitogenic effect is at least 
partly mediated via 5HT1b receptors. Subendothelial cell proliferation is 
significantly elevated in human carcinoid valves In vivo. The data suggest a 
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mechanism whereby serotonin may contribute to valvular proliferation in 
carcinoid heart disease28. 
9. Steven Droogmans et al (2007) reported the In vivo model of drug –induced 
valvular heart disease in rat, pergolide – induced valvular heart disease 
demonstrated with echocardiography and correlation with pathology.thirty 
male wister rats were given daily injection of pergolide serotonin and vehicle 
for 5 month, echocardiography demonstrated the presence of aortic 
regurgitation in serotonin and in pergolide compared with normal. 
Histological examination revealed the presence of diffused thickened and 
myxoid aortic, mitral and tricuspid valves in serotonin and pergolide animal 
as seen in VHD29. 
10. Bjorn.I.Gustafsson MD et al (2005) reported the Long-term serotonin 
administration induces heart disease  in rats.  rats dosed with serotonin 
develope changes similar to those seen in human carcinoid heart disease. Ten 
Sprague -Dawley rats were given serotonin injections subcutaneously once 
daily for 3 months, controls were given saline. A long-lasting 
hyperserotoninemia with a >10-fold increase in both platelet-poor plasma and 
dialysate from the femoral muscles appeared. The animals developed clinical 
signs such as flushing and loose stools. After 3 months, 6 of 10 rats given 
serotonin had pathological echocardiographs. Two animals had a 
combination of aortic and pulmonary valve insufficiency, 1 had isolated 
aortic valve insufficiency, and 3 had isolated pulmonary valve insufficiency. 
Histopathological examination revealed shortened and thickened aortic cusps 
and carcinoid like plaques characterized by a collection of myofibroblasts 
within an extracellular matrix of collagen ground substance30.  
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11. Karl Engelman M.D et  al (2005) reported the Inhibition of Serotonin 
Synthesis by Para-Chlorophenylalanine in Patients with the Carcinoid 
Syndrome. the role of 5-hydroxytryptamine (serotonin, 5HT) in the 
pathophysiology of the carcinoid syndrome, and especially in flush 
production, has been seriously questioned,2 the fact remains that increased 
production of serotonin is a hallmark of the condition. If it were possible 
effectively to inhibit the formation of this pharmacologically potent amine in 
patients with carcinoid tumours, a likely result would be a better 
understanding of the clinical significance of serotonin. A possibility of 
achieving this goal appeared with the studies of Koe  and Weissman  showing 
that para-chlorophenylalanine (PCP) is a potent and selective depletor of 
tissue serotonin in animals31. 
12. Sandeepa Musunuru et al (2005) reported  A Mouse Model of carcinoid 
syndrome and Heart disease. Seventeen nude mice underwent intrasplenic 
injection of human pancreatic carcinoid BON cells (107) and then were 
euthanized 9 weeks later. Murine livers were analyzed by 
immunohistochemistry. Murine hearts were sectioned and the surface area of 
the right heart valves determined. Blood was also collected and analyzed for 
platelet serotonin by ELISA.32 
13. J M Zuetenhorst et al (2004) reported the  Role of natriuretic peptides in the 
diagnosis and treatment of patients with carcinoid heart disease. Carcinoid 
heart disease (CHD) occurs in 20-70% of the patients with metastatic well-
differentiated Neuro Endocrine Tumours (NET). To evaluated 
whether natriuretic peptides (ANP or NT-proBNP) are useful in early 
detection of CHD. Blood samples from 32 patients with NET were compared 
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with cardiac ultrasound follow-up. CHD was defined as thickening of the 
tricuspid valve in the presence of grade III-IV/IV tricuspid valve 
regurgitation. CHD was found in nine out of 32 patients (28%), all with 
symptoms of the carcinoid syndrome compared to 65% in the 23 patients 
without CHD (P=0.04). Median levels of NT-proBNP and 5-HIAA were 
significantly higher in patients with CHD (894 ng l(-1) and 815 micromol 24 
h(-1)) compared to those without (89 and 206 ng l(-1), P<0.001 and 
P=0.007). No significant differences were detected in ANP levels (P=0.11). 
Dilatation of the right atrium and ventricle as well as thickening of the 
tricuspid valve and degree of regurgitation were statistically significant 
correlated with NT-proBNP levels. The accuracy of NT-proBNP in the 
diagnosis of CHD was higher than that of ANP. A significantly better 
survival was observed in case of normal NT-proBNP values. In conclusion, 
NT-proBNP is helpful as a simple marker in the diagnosis of CHD33.  
14. Zuetenhorst et al   (2003) reported the Carcinoid heart disease: the role of 
urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial 
natriuretic peptide, transforming growth factor-beta and fibroblast growth 
factor. Serotonin excretion plays a role in the development of carcinoid heart 
disease (CHD), but the exact pathogenesis is not known. In the current study, 
To evaluated 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) 
excretion, as well as plasma levels of transforming growth factor-beta (TGF-
beta), fibroblast growth factor (FGF), and atrial natriuretic peptide (ANP) in 
patients with and without CHD determined by ultrasound examination. Urine 
and plasma samples were obtained for 37 patients and cardiac ultrasound was 
performed during follow-up in 1999 and 2000. Median 5-HIAA excretion 
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was calculated for the period between diagnosis and ultrasound 
examination.34 
15. Jacob E. Møller, M.D, Ph.D et al (2003) Factors Associated with Progression 
of Carcinoid Heart Disease  sample included 71 patients with the carcinoid 
syndrome who underwent serial echocardiographic studies performed more 
than one year apart and 32 patients referred directly for surgical intervention 
after an initial echocardiographic evaluation. A score for carcinoid heart 
disease was determined on the basis of an assessment of valvular anatomy 
and function and the function of the right ventricle. An increase of more than 
25 percent in the score between studies was considered suggestive of disease 
progression. Tumor progression was assessed on the basis of abdominal 
computed tomographic scans and changes in the level of urinary 5-
hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin35. 
16. Rosenzweig - Lipson S et al (2002) serotonin induces up regulation of 
transforming growth factor-β in aortic valve interstitial cells via 5-
HT2 receptors and that transforming growth factor-β stimulates 
glycosaminoglycan production in sheep aortic valve interstitial cells.36 
17. Watanabe T et al (2001) Serotonin potentiates angiotensin II - induced 
vascular smooth muscle cell proliferation. investigated the growth promoting 
activities of two potent vasoactive substances, angiotensin II (Ang II) 
and serotonin (5-HT), on cultured rabbit VSMCs37. 
18. Watanabe T et al (2001) reported the serotonin potentiates angiotensin II--
induced vascular smooth muscle cell proliferation. Vascular smooth muscle 
cell (VSMC) proliferation is a key feature in the development of 
atherosclerosis and restenosis after angioplasty, which can occur in response 
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to many different humoral and mechanical stimuli. To investigated the 
growth promoting activities of two potent vasoactive substances, angiotensin 
II (Ang II) and serotonin (5-HT), on cultured rabbit VSMCs. Growth-arrested 
VSMCs were incubated with serum-free medium containing different 
concentrations of Ang II in the presence or absence of 5-HT. [3H] thymidine 
incorporation into VSMC DNA was measured as an index of cell 
proliferation. Ang II and 5-HT stimulated DNA synthesis in a dose-
dependent manner with a maximal effect at 1.75 microM for Ang II (202%) 
and 50 microM for 5-HT (205%)38. 
19. Di Lazio S et al (2000) reported the Carcinoid Heart Disease, Carcinoid 
syndrome originates from metastatic carcinoid tumours localized in the 
gastrointestinal system, pancreas, biliary vessels, bronchi, ovaries, and testes; 
it is characterized by flushing,  diarrhoea, bronchoconstriction, and fibrous 
endocardial plaques in the heart. Cardiac involvement is detected by 
echocardiography in over 50% of patients with this syndrome. Right-sided 
valvular heart disease occurs frequently in patients with carcinoid syndrome, 
involving most commonly the tricuspid and pulmonary valves. Involvement 
of the left-sided valves rarely occurs39. 
20. Paul Egermayer et al (1999) reported the Role of serotonin in the 
pathogenesis of acute and chronic pulmonary hypertension. The 
pathophysiology of pulmonary hypertension cannot be fully understood in 
terms of a traditional single cause and effect model. The concept of a balance 
of factors is probably more helpful. Under different circumstances three 
general, often interrelated, types of response are apparent, 
vasodilation/vasospasm, mitogenesis/cytostasis, and thrombosis/fibrinolysis. 
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Although the vascular response to insult often appears relatively stereotyped, 
causes are invariably multifactorial. The role of serotonin in other varieties of 
pulmonary hypertension has been unjustly neglected40.  
21. Hurst RD et al (1995) reported the Octreotide inhibition of serotonin-induced 
ileal chloride secretion.  It  inhibits 5HT-stimulated electrogenic chloride 
secretion at the mucosal level. Additionally this inhibitory effect of octreotide 
is likely mediated by activation of the inhibitory subunit of membrane-bound 
GTP-binding regulatory proteins. These results thus provide experimental 
evidence in support of the ability of SMS to ameliorate the carcinoid 
diarrhoea by a direct effect on stimulated mucosal ion secretion41. 
22. L Lundin et al (1988) reported the Carcinoid heart disease: Relationship of 
circulating vasoactive substances to ultrasound-detectable cardiac 
abnormalities ,Cardiac ultrasound investigation of 68 prospectively studied 
patients with histologically proven midgut carcinoid tumours showed right 
heart disease in 66%. The abnormal findings included morphologic and 
functional aberrations of the tricuspid valve in 52% and 83%, respectively, 
right atrial and ventricular enlargement in 53% and 30%, and paradoxical 
systolic septal contractions in 19%. The patients with the most pronounced 
right heart disease had significantly higher (p less than .01) plasma levels of 
the tachykinins neuropeptide K and substance P as well as higher (p less than 
.001) urinary excretion of the serotonin metabolite 5-hydroxyindoleacetic 
acid. These patients also had the most extensive tumor disease. The 
occurrence of echocardiographic abnormalities of the left heart was similar to 
that in healthy individuals of the same age, but abnormalities were less 
frequent among the patients with severe right heart disease. The severity of 
REVIEW OF LITERATURE 
Institute of Pharmacology, MMC.  Page | 26 
 
cardiac involvement does not seem to be related to the duration of carcinoid 
disease but more to the extent of the disease, i.e., higher plasma levels of 
serotonin and tachykinins.42 
23. Jacob E. Møller, MD et al (2005) reported the  Prognosis of Carcinoid Heart 
Disease, Analysis of 200 Cases Over Two Decades. The long-term prognosis 
of patients who develop carcinoid heart disease and the effect of cardiac 
surgery on outcome are not well established. In this retrospective study, 
identified 200 patients with carcinoid syndrome referred for 
echocardiography in whom the diagnosis of carcinoid heart disease was 
confirmed. Patients were divided into 3 groups of similar size according to 
the date from first diagnosis of carcinoid heart disease. Group A comprised 
patients diagnosed from 1981 through June 1989; group B, diagnosed July 
1989 through May 1995; and group C, June 1995 through 2000. The end 
point was all-cause mortality. Median survival was significantly lower in 
group A (1.5 years, 95% CI 1.1 to 1.9 years) compared with groups B (3.2, 
95% CI 1.3 to 5.1 years) and C (4.4, 95% CI 2.4 to 7.1 years; P=0.009). In a 
multivariate model adjusted for treatment and clinical characteristics, the risk 
of death in groups    B (hazard ratio 0.67, 95% CI 0.46 to 0.99, P=0.04) and 
C (hazard ratio 0.61, 95% CI 0.39 to 0.92, P=0.006) was significantly 
reduced relative to group A. Cardiac surgery was performed in 87 patients. 
When cardiac surgery was included as a time-dependent covariate in a 
multivariate analysis, it was associated with a risk reduction of 0.48 (95% CI 
0.31 to 0.73, P<0.001), whereas the time period of diagnosis was no longer 
significant. The prognosis of patients with recognized carcinoid heart disease 
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has improved over the past 2 decades at our institution. This change in 
survival may be related to valve replacement surgery43. 
24. P A Pellikka et al (1993) reported the Carcinoid heart disease. Clinical and 
echocardiographic spectrum in 74 patients. The echocardiographic, Doppler, 
and clinical features of the 74 patients (56%) with echocardiographic 
evidence of carcinoid heart disease are described. Among these patients, 97% 
had shortened, thickened tricuspid leaflets. Tricuspid regurgitation was 
present in all 69 patients with carcinoid heart disease who underwent Doppler 
examination, and it was of moderate or severe degree in 62 patients (90%)44.  
 
25. Howard RJ, Drobac M, Rider WD et al.(1962) Carcinoid  heart  disease:  
Diagnosis  by  two-dimensional echocardiography45. 
REVIEW OF GANODERMO LUCIDUM: 
1. Lasukova TV et al (2015)  reported the Cardio protective activity of Ganoderma 
lucidum Extract during total ischemia and reperfusion of isolated heart. The cardio 
protective effects of Ganoderma lucidum extract were examined in experiments 
with global ischemia (45 min) and reperfusion (30 min) of isolated and perfused 
rat heart. The course of  preventive administration of the extract in a dose of 400 
mg/kg for 15 days diminished necrotic death of cardiomyocytes and reduced 
reperfusion contracture. Ganoderma lucidum extract 
demonstrated antioxidant properties. Cardio protective properties of Ganoderma 
lucidum extract are largely determined by its antioxidant properties46. 
2. Zengenni Liang et al (2014) Chemical Characterization and Antitumor Activities 
of Polysaccharide Extracted from Ganoderma lucidum. In which polysaccharide 
(GLP) is a biologically active substance reported to possess anti-tumor ability. 
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The mechanisms of GLP-stimulated apoptosis are still unclear. This study aims to 
determine the inhibitory and apoptosis-inducing effects of GLP on HCT-116 cells. 
They found that GLP reduced cell viability on HCT-116 cells in a time- and dose-
dependent manner, which in turn, induced cell apoptosis. The observed apoptosis 
was characterized by morphological changes, DNA fragmentation, mitochondrial 
membrane potential decrease, S phase population increase, and caspase-3 and -9 
activation. Furthermore, inhibition of c-Jun N-terminal kinase (JNK) by SP600125 
led to a dramatic decrease of the GLP-induced apoptosis. Western blot analysis 
unveiled that GLP up-regulated the expression of Bax/Bcl-2, caspase-3 and poly 
(ADP-ribose) polymerase (PARP). These results demonstrate that apoptosis 
stimulated by GLP in human colorectal cancer cells is associated with activation 
of mitochondrial and mitogen -activated protein kinase (MAPK) pathways.47 
3. Sun-he jang et al (2014) reported the hepatoprotective evaluation of Ganoderma 
lucidum pharmacopuncture: In vivo studies of ethanol-induced acute liver injury. 
Apoptotic changes are inhibited by the addition of antioxidants and glp, 
suggesting that oxidative stress is involved in the release of cytochrome c, which 
precedes apoptosis in hepatocytes exposed to ethanol. therefore, glp suppresses 
apoptosis by regulating mitochondrial-damage-mediated endogenous pathways, 
which could be one of the important mechanisms for preventing alcoholic-induced 
liver injury. in conclusion, the present study has revealed that glp protects against 
ethanol -induced hepatic injury in SD rats by modulating the activities of ethanol-
metabolizing enzymes and attenuating oxidative stress48. 
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4. Tran HB et al (2014) reported the Hypotensive effects and angiotensin-converting 
enzyme inhibitory peptide of reishi (ganodermo lingzhi)  auto-digested extracted. 
Reishi's own proteases to hydrolyze its protein and obtained auto-digested reishi 
(ADR) extract. The extract was subjected to in vitro assays and administered to 
spontaneous hypertensive rats (SHRs) to determine its potential for use as a 
hypotensive medication. Bioassay-guided fractionation and de novo sequencing 
were used for identifying the active compounds. After 4 h administration of ADR, 
the systolic pressure of SHRs significantly decreased to 34.3 mmHg (19.5% 
change) and the effect was maintained up to 8 h of administration, with the 
decrease reaching as low as 26.8 mmHg (15% reduction-compare to base line a 
decrease of 26.8 mmHg is less than a decrease of 34.3 mmHg so it should give a 
smaller % reduction). Eleven peptides were identified and four of them showed 
potent inhibition against ACE with IC50 values ranging  
from 73.1 μM to 162.7 μM49. 
5. Deng pan et al (2013) reported the Antidiabetic, Antihyperlipidemic and 
Antioxidant Activities of a Novel Proteoglycan from Ganoderma lucidum 
Fruiting Bodies on db/db Mice and the Possible Mechanism FYGL was an 
effective antidiabetic agent by enhancing insulin secretion and decreasing hepatic 
glucose output along with increase of adipose and skeletal muscle glucose 
disposal in the late stage of diabetes. Furthermore, FYGL is beneficial against 
oxidative stress, thereby being helpful in preventing the diabetic complications50. 
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6. Shih-Fen Liao et al (2013) reported the Immunization of fucose-containing 
polysaccharides from Reishi mushroom induces antibodies to tumor-associated 
Globo H-series epitopes. Carbohydrate-based vaccines have shown therapeutic 
efficacy for infectious disease and cancer. The mushroom Ganoderma lucidum 
(Reishi) containing complex polysaccharides has been used as antitumor 
supplement, They  show that the mice immunized with a L-fucose (Fuc)-enriched 
Reishi polysaccharide fraction (designated as FMS) induce antibodies against 
murine Lewis lung carcinoma cells, with increased antibody-mediated 
cytotoxicity and reduced production of tumor-associated inflammatory mediators 
(in particular, monocyte chemoattractant protein-1)51. 
7. Sudheesh NP et al (2013) Ganoderma lucidum ameliorate mitochondrial damage 
in isoproterenol - induced myocardial infarction in rats by enhancing the actities 
of TCA cycle enzymes and respiratory chain complexes. Cardiac toxicity was 
assessed by determining the activities of creative kinase (CK) and lactate 
dehydrogenises (LDH) after subcutaneous injection of ISO (85 mg/kg) at an 
interval of 24h for 2 days. The animals were sacrificed 24h after last ISO 
administration. G. lucidum (100 and 250 mg/kg, pod.) was given to the rats once 
daily for 15 days prior to the ISO challenge. Similarly, α-Tocopherol (100mg/kg, 
p.o) was kept as the standard. To assess the extent of cardiac mitochondrial 
damage, the activities of Krebs cycle dehydrogenises and mitochondrial 
complexes I, II, III, and IV as well as the level of ROS and mitochondrial 
membrane potential (ΔΨmt) were evaluated. Administration of G. lucidum and α-
tocopherol significantly protected the elevated activities of CK and LDH52. 
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8. Bang-Jau You et al (2013) reported the  A Novel Approach to Enhancing 
Ganoderic Acid Production by Ganoderma lucidum Using Apoptosis ,  This study 
investigated the role of apoptosis signaling on GA biosynthesis and presented a 
novel approach, namely apoptosis induction, to increasing GA production. Aspirin 
was able to induce cell apoptosis in G. lucidum, which was identified by terminal 
deoxynucleotidyl transferase mediated dUPT nick end labeling assay positive 
staining and a condensed nuclear morphology. The maximum induction of 
lanosta-7,9(11), 24-trien-3α-01-26-oic acid (ganoderic acid 24, GA24) production 
and total GA production by aspirin were 2.7-fold and 2.8-fold, respectively, after 
1 day. Significantly lower levels of GA 24 and total GAs were obtained after 
regular fungal culture for 1.5 months. ROS accumulation and phosphorylation of 
Hog-1 kinas, a putative homolog of MAPK p38 in mammals, occurred after 
aspirin treatment indicating that both factors may be involved in GA biosynthetic 
regulation. However, aspirin also reduced expression of the squalene synthase and 
lanosterol synthase coding genes, suggesting that these genes are not critical for 
GA induction54. 
9. Michelle M  et al (2011) reported the Ganoderma lucidum (Reishi) Inhibits 
Cancer Cell Growth and Expression of Key Molecules in Inflammatory Breast 
Cancer. effects of Reishi on viability, apoptosis, invasion, and its mechanism of 
action in IBC cells (SUM-149). Results show that Reishi selectively inhibits 
cancer cell viability although it does not affect the viability of noncancerous 
mammary epithelial cells55 
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10. Xue H et al (2010) reported the  Effect of Ganoderma lucidum polysaccharides 
on hemodynamic and antioxidation in T2DM.  Rats were fed high-fat diet for 4 
weeks and then were injected STZ (30 mg x kg(-1)) to induce the type 2 
diabetes mellitus (T2DM). Once the T2DM models were set successfully, rats 
were randomized into six groups: normal group (NG), group of diabetes 
mellitus (DMG), groups of low dosage (GLPs-LG), middle dosage (GLPs-MG), 
high dosage (GLPs-HG) and berberine (BerG). They received GLPs with 
different dosages (200, 400, 800 mg x kg(-1)) and berberine (30 mg x kg(-1)) 
continually for 16 weeks. At 16th week end, the following indices of rats were 
measured respectively: blood glucose, hemodynamic including LVSP, LVEDP, 
dp/dt(max) and dp/dt(max) and the contents of NO, SOD, MDA, GSH-Px, CAT 
in cardiac tissue. Besides, myocardial ultra structure was observed by electron 
microscope. Both the middle dosage and the high dosage of GLPs could low 
blood glucose effectively, and they could reduce LVEP but increase -
dp/dt(max). Meanwhile, they could activate GSH-Px, CAT, SOD, NO, but 
reduce MDA in cardiac tissue and improve the myocardial ultrastructure56. 
11. Sudheesh NP et al (2010) reported the Therapeutic potential of Ganoderma 
lucidum (Fr.) P. Karst. against the declined antioxidant status in the mitochondria 
of post-mitotic tissues of aged mice.  estimating the activities of manganese-
superoxide dismutase (Man SOD), glutathione peroxidase (GPx), glutathione-S-
transferase (GST) and catalase (CAT) as well as levels of reduced glutathione 
(GSH), lipid peroxidation, advanced oxidation protein products (AOPP) and 
reactive oxygen species (ROS) in the heart and brain mitochondria of aged mice 
after oral administration of ethanolic extract of G. lucidum (50 and 250mg/kg), 
once daily for 15 days. The effect was compared with that of aged and young 
control animals57.  
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12. Keith R Martin et al (2010) Both common and specialty mushrooms inhibit 
adhesion molecule expression and in vitro binding of monocytes to human aortic 
endothelial cells in a pro-inflammatory environment, Human aortic endothelial 
cells (HAEC) were incubated overnight with control media with 
dimethylsulfoxide (DMSO) vehicle (1% v/v) or containing DMSO extracts of 
whole dehydrated mushrooms (0.1 mg/mL), which included Agaricus 
bisporus (white button and crimini), Lentinula edodes (shiitake), Pleurotus 
ostreatus (oyster), and Grifola frondosa (maitake). Monolayers were subsequently 
washed and incubated with medium alone or containing the pro-inflammatory 
cytokine IL-1β (5 ng/mL) for 6 h to upregulate pro-atherosclerotic adhesion 
molecules (AM). AM expression was assayed by ELISA and binding of U937 
human monocytes pre-loaded with fluorescent dye was determined58. 
13. KK Janardhanan et al (2005) reported  to evaluate the protective effect of 
Ganoderma lucidum extract against doxorubicin-induced cardiotoxicity. 
Administration of 3 doses of doxorubicin,6 mg/kg body weights, i.p. per each 
dose, alternative days, showed clear signs of cardio toxicity in rats. The drug 
enhanced serum creatine kinase (CK) activity and lipid peroxidation in tissue 
drastically. The drug also induced significant decrease in GSH level and activities 
of CAT, SOD and GPx. Administration of methanolic extract of G.lucidum  (500 
and 1,000 mg/kg body weight) significantly increased the level of GSH and 
activities of CAT, SOD and GPx. Activity of CK was significantly lowered in a 
dose dependent manner. The treatment also caused significant decrease in lipid 
peroxidation (MDA). The results thus indicated that methanolic extract of 
Ganoderma.lucidum prevented oxidative stress caused by doxorubicin 
administration and the increase in serum CK activity and lipid peroxidation in the 
REVIEW OF LITERATURE 
Institute of Pharmacology, MMC.  Page | 34 
 
tissue. The experimental findings suggest the therapeutic potential of G.luciduma 
adjuvant in cancer chemotherapy59. 
16. Woo CW et al (2005) reported the Ganoderoma lucidum inhibits inducible nitric 
oxide synthase expression in macrophages.  To investigate the effect of G. 
lucidum on iNOS-mediated NO production in macrophages. Human monocytic 
cell (THP-1) derived macrophages were incubated with lipopolysaccharide (LPS) 
for 24 h. Such treatment significantly stimulated NO production (253% versus the 
control). Such a stimulatory effect was resulted from increased iNOS mRNA 
expression (270% versus the control) and iNOS activity (169.5% versus the 
control) in macrophages. The superoxide anion level was also elevated (150% 
versus the control) in LPS-treated macrophages.  G. lucidum may exert a 
therapeutic effect against atherosclerosis via ameliorating iNOS-mediated NO 
overproduction in macrophages60. 
17. Wong KL et al (2004) reported the Antioxidant activity of Ganoderma lucidum 
in acute ethanol-induced heart toxicity.  The mice were divided into six groups 
with ten animals in each group. Ganoderma lucidum, at doses of 10, 25 and 50 
mg/kg (pod) was administered. Superoxide anions were assayed by UV 
spectrophotometer using the cytochrome C reduction method. The results of this 
study showed that Ganoderma lucidum exhibited a dose-dependent 
antioxidative effect on lipid peroxidation and superoxide scavenging activity in 
mouse heart homogenate. Additionally, this result indicated that heart damage 
induced by ethanol shows a higher malonic dialdehyde level compared 
with heart homogenate treated with Ganoderma lucidum. It is concluded that the 
antioxidative activity may therefore contribute to the cardioprotective effect of 
Ganoderma lucidum, and may therefore protect the heart from superoxide 
induced damage61. 
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18. You YH et al (2003) reported the Antioxidant effect of Ganoderma 
polysaccharide peptide, Copper was used as oxidant to induce low lipoprotein 
(LDL) oxidative modification, and alloxan was given i.v. to induce reactive 
oxygen species (ROS) injury in mice. GLPP decreased oxidation of LDL and the 
relative electrophoretic mobility (REM) of oxidative product of LDL. After 
GLPP was given i.p. for 20 days, the concentration of malondialdehyde (MDA) 
in serum and heart of mice was decreased. The GSHpx enzyme activity was 
increased, while the SOD level was decreased. The catalase (CAT) levels were 
not significantly changed by GLPP62. 
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V. AIM & OBJECTIVE: 
 
 To evaluate the  antioxidant effect of red reishi mushroom  
         (Ganoderma lucidum) by in vitro methods. 
 
 To evaluate the inhibitory effect of Ganoderma lucidum on serotonin 
induced carcinoid heart disease in rats. 
 
 
 
 
 
 
 
 
PLAN OF WORK 
Institute of Pharmacology, MMC.  Page | 37 
 
VI. PLAN OF WORK: 
Serotonin creatinin sulphate complex purchased from sigma Aldrish company in 
Germany. 
Pure red reishi mushroom procured form United States of America. 
Digoxin purchased from Jayam medical in Chennai.  
 
   
 
In vitro method    
   
 
PHARMACOLOGICAL  SCREENING OF  
GANODERMA  LUCIDUM
In vitro Method In vivo Method
1  Superoxide radical  scavenging activity
2  Hydroxyl radical scavenging  assay
3  Nitric oxide radical scavenging assay
4  Phosphomolybdenum assay
PLAN OF WORK 
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In vivo method 
        
                     
 
 
 
                                             
Electrocardiogram(ECG) was taken before starting the 
drug treatment to the animal
ANIMALS DIVIDED INTO 4 GROUPS &
DRUG TREATMENT GIVEN FOR 3 MONTHS
Control Serotonin 
Serotonin
+
digoxin
Serotonin
+
Ganoderma 
lucidum
Echocardiogram and Electrocardiogram was 
taken at end of 3 months
Heart valve thickness  measurement 
HISTOPATHOLOGICAL STUDY
Sacrificing the animal     
Heart and liver weight measurement
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VII. METHODOLOGY: 
 Reactive Oxygen Species Assay 
  SUPER OXIDE FREE RADICAL SCAVENGING ACTIVITY:  
Super oxide is biologically important as it can form singlet oxygen and 
hydroxyl radical. Overproduction  of  super  oxide  anion  radical  contributes  to  
redox  imbalance  and associated  with  harmful  physiological  consequences. 
Super  oxide  anion  are  generated in  PMS-NADH  system  by  the  oxidation  
of  NADH  and  assayed  by  the  reduction  of  NBT resulting in the formation of blue 
formazan. 100  µl  of  Riboflavin  solution  [20  µg],  200  µl  EDTA  solution  
[12mM],  200  µl  methanol and  100  µl  NBT  (Nitro-blue  tetrazolium)  solution  
[0.1mg]  were  mixed  in  test  tube  and reaction mixture was diluted up to 3 ml with 
phosphate buffer [50mM].  
The absorbance of solution was measured at 590nm using phosphate buffer as 
blank after illumination for   5  min.  This   is  taken  as  control.  50  µl  of  different  
concentrations  of  coumarin compounds  as  well  as  standard  preparation  were  
taken  and  diluted  up  to  100  µl  with methanol. To each of these, 100 µl 
Riboflavin, 200 µl EDTA, 200 µl methanol and 100 µl NBT was mixed in test tubes 
and further diluted up to 3 ml with phosphate buffer. Absorbance  was  measured  
after  illumination  for  5  min.  at  590  nm  on  UV  visible spectrometer . The 
IC50value for test and standard preparation were calculated.  
%  Super oxide Free Radical scavenging/Inhibition : 
 [Absorbance of control - Absorbance of test sample/Absorbance of control] X 100 
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HYDROXYL RADICAL SCAVENGING ACTIVITY: 
The scavenging activity of test sample on hydroxyl radical was measured according 
to the method of Klein et al (1992). Various concentrations of test sample were added with 
1.0ml of iron‐EDTA solution (0.13% ferrous ammonium sulfate and 0.26% EDTA), 0.5ml of 
EDTA solution (0.018%), and 1.0mL of dimethyl sulphoxide (DMSO) (0.85% v/v in 0.1M 
phosphate buffer, pH 7.4).The reaction was initiated by adding 0.5ml of ascorbic acid 
(0.22%) and incubated at 80–90°C for 15 min in a water bath. After incubation the reaction 
was terminated by the addition of1.0mL of ice‐cold TCA (17.5% w/v). 3ml of Nash reagent 
was added and left at room temperature for 15min. The reaction mixture without sample was 
used as control. The intensity of the color formed was measured spectroscopically at 412 nm. 
The % hydroxyl radical scavenging activity is calculated by the following formula:  
% Hydroxyl radical scavenging activity = [(Control OD-Sample OD)/Control OD] X100. 
NITRIC OXIDE RADICAL SCAVENGING ACTIVITY: 
2 mL of 10 mM sodium nitro prusside in 0.5 mL phosphate buffer saline (pH 
7.4) was mixed with sample. Various concentration of sample was taken and the 
mixture was incubated at 25degree for 150 min. From the incubated mixture 0.5 mL 
was taken out and added into 1.0 mL sulfanilic acid reagent (33% in 20% glacial 
acetic acid) and incubated at room temperature for 5 min. finally, 1.0 mL naphthyl 
ethylene diamine dihydrochloride (0.1% w/v) was mixed and incubated at room 
temperature for 30 min before measuring the absorbance at 540 nm was measured 
with a spectrophotometer. (Garrat D C et al., 1964) 
 The nitric oxide radical scavenging activity was calculated as: 
% Nitric oxide scavenging potential = [(Control OD-Sample OD)/Control OD] X100. 
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PHOSPHOMOLYBDENUM ASSAY: 
The antioxidant activity of samples was evaluated by the green 
phosphomolybdenum complex formation according to the method of Prieto et al 
(1999). Various concentration of the test sample was combined with 1ml of reagent 
solution (0.6M sulphuric acid, 28mM  sodium phosphate and 4mM ammonium 
molybdate). The vials were capped and incubated in a water bath at 95°C for 90 min. 
After the samples had cooled to room temperature, the  absorbance of the mixture was 
measured at 695 nm against a blank.  
The reduction activity was calculated as:  
% Phosphomolybdenum reducing potential = [(Sample OD-Control 
OD)/Sample OD] X100. 
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IN VIVO METHOD 
ANIMALS: 
 The present study was conducted after obtaining approval from the 
Institutional Animal Ethics  committee vide approval no: 11/243/CPCSEA and 
this protocol met the requirement of national guidelines  of  CPCSEA. 
 All the animals used in this study were obtained  from the animal house of 
Madras Medical College, Chennai-3. 
Albino Wistar Rats:  Young mature female Albino Wistar Rats weighing about100 
to 200g were used which were obtained from the inbred colony of  animal house of 
Madras Medical College, Chennai-3. 
Appliances/Equipment: 
Drug was administered by using the Rat tube for oral gavage made with 
stainless steel having  blunt  end.  The  rat  oral  gavage  tube  was  connected  to  the  
5ml/1ml  syringe  for  the administration of required quantity of the drug. Tuberculin 
syringe with the capacity of 1ml has been used for the administration of the small 
quantity of the drugs. 
Housing: 
The animals were housed in well ventilated and air-conditioned animal house 
which was maintained at a constant temperature 23 ± 2°C with a relative humidity 
retained at 55-60%. Lighting was 12 hours light and 12 hours dark. The animals were 
housed in spacious polypropylene cages and paddy husk was utilized as bedding 
material. 
 
MATERIALS AND METHODS 
Institute of Pharmacology, MMC.  Page | 43 
 
Diet and water: 
The animals were maintained on a diet of   standard pellet & purified water. 
They  were provided with food and water ad libitum  
Animal Identification: 
All the animal cages used in the study had proper identification i.e., labels 
bearing group name, weight of the animals, the drug and its volume to be 
administered according to their body weights. Animals in the cages marked with 
markers in tail, ear and head. 
Serotonin  Preparation And Administration: 
Serotonin (5-HT Creatinin Sulphate Complex, Sigma-Aldrich) was dissolved 
in physiological saline at a concentration of 20 mg/mL. In order to avoid skin lesions 
like subcutaneous bleedings and traumatic wounds, the injection site was changed 
daily. An equal volume of physiological saline (1 mL/kg) was given to the placebo 
rats. 
Red Reishi Mushroom Preparation: 
The contents of the capsule of Reishi mushroom was dissolved in distilled 
water at a concentration of 50mg/ml. 
Digoxin stock solution  preparation: 
Digoxin was dissolved in distilled water at a concentration of 0.25mg/100ml. 
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EXPERIMENTAL DESIGN: 
S.NO GROUPS DRUG GIVEN DOSE NO OF           
ANIMALS 
DURATION 
OF  DOSE 
1 Group  1 Saline    1ml/kg 
(p.o)     
         6 3  months 
2 Group  2 Serotonin  20mg/kg  
(s.c) 
         6 3 months 
3 Group  3 Serotonin  
      + 
Digoxin 
20mg/kg 
(s.c) 
     + 
1.25mcg/kg 
(p.o) 
          6 3 months 
4 Group  4 Serotonin 
+  
Red reishi 
mushroom 
(Ganoderma 
Lucidum) 
20mg/kg  
(s.c) 
      + 
500mg/kg 
(p.o) 
         6  3 months 
                                          Total no of animals                                          24 
Table: 1        Rats were given daily serotonin injections subcutaneously ( 20 mg/kg );  
control were given saline. The serotonin was dissolved in saline just before it was 
injected. Digoxin was used as a standard in comparison to Red Reishi mushroom as it 
had been used to treat cardiac failure following carcinoid induced by serotonin . 
The last injections were given 1 week before the rats were euthanized. At 
euthanization, the animals were weighed30 . 
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ELECTROCARDIOGRAM:  
ECG was taken before and  after the drug treatment for all animals at Madras 
Veterinary College, Chennai . 
ECHOCARDIOGRAPHY: 
Ten minutes before imaging, the rat was anesthetized with 80 mg/kg ketamine 
intraperitoneally. Subsequently the anterior chest wall was shaved and the rat was 
placed in left lateral decubitus on a wooden bench in order to obtain optimal image 
quality. 
A Vivid 7 Pro system  with a 25 MHz neonatal probe (10S) was used. Images 
and loops were stored digitally for post-test analysis. The image sector was kept 
narrow in order to get a maximal frame rate. When necessary, cineloop speed was 
reduced for optimal jet evaluation. Regurgitant jets were assessed visually with 2D 
colour Doppler and continuous-wave Doppler in the parasternal short and long axis, 
apical three and four chamber views. If no retrograde flow was detectable with 2D 
colour Doppler or continuous-wave Doppler, regurgitation was considered absent.  
The pulmonary regurgitant flows were coded as present or absent in the short-axis 
view29. 
Echocardiography was performed at Madras Veterinary College, Chennai. 
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HISTOPATHOLOGY: 
The hearts were weighed and fixed in formalin for 2 h. Then they were 
embedded in paraffin, cut in an axial plane (from basis to apex) and stained with 
hematoxylin and eosin and alcian blue for glycosaminoglycans. Additional step 
sections, ranging from 1 to 3 (approximately 100 µg/ml between sections) were 
carried out for those heart sections without valves. Extreme care was taken in 
sectioning the heart so that the valves were mainly cut transversely (with the 
attachment sides of the leaflets visible on both ends of the valve). 
The program was calibrated with a graduated slide. Microscopic images were 
used to evaluate blindly the cardiac valves and cardiomyocytes. The maximum 
thickness of every valve present was measured. The width of  cardiomyocytes was 
measured on the left ventricle of each section29. 
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VIII. RESULTS: 
SUPER OXIDE ANION RADICAL SCAVENGING ACTIVITY: 
S.No Concentration 
(µg/ml) 
% inhibition 
of Standard 
% Inhibition of Test 
1 200 39.18 34.26 
2 400 46.71 38.23 
3 600 51.81 45.29 
4 800 67.98 55.73 
5 1000 72.74 60.29 
6 1200 87.41 73.23 
7 IC 50 value 691.04 µg/ml 714.36 µg/ml 
    
             Table:2     
 
     
Fig:8    Graphical Representation Of  Super Oxide Anion Radical Scavenging Activity. 
IC 50 Value of  Test (714.36µg/ml) was closely related to  standard value  (691.04 µg/ml). 
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HYDROXYL RADICAL  ASSAY: 
S.No Concentration  
(µg/ml) 
% Inhibition of  
standard 
% Inhibition of test 
1 200 29.72     30.42 
2 400 39.61 40.39 
3 600 49.99 45.35 
4 800 58.41 49.88 
5 1000 72.61 67.03 
6 1200 87.18 75.74 
    IC 50 value 669.04µg/ml 687.45 µg/ml 
Table:3  
 
Fig: 9,Graphical representation of   Hydroxyl  Radical assay. 
IC 50 Value  of  Test (687.45µg/ml) was closely related to  standard value  (691.04µg/ml). 
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NITRIC OXIDE ASSAY: 
S.NO CONCENTRATION (µg/ml) 
% Inhibition of  
Standard 
% Inhibition of 
Test 
1 50 38.61 32.35 
2 100 42.71 43.88 
3 150 59.38 57.03 
4 200 76.31 69.74 
5 250 79.43 78.16 
6 300 85.56 80.34 
 IC50 value 496.58 µg/ml 459.23 µg/ml 
 
Table:4 
 
 
Fig: 10   Graphical representation of   Nitric  oxide assay. 
IC 50 Value  of  Test  (496.58µg/ml)  was closed related to standard value (459.23 µg/ml). 
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PHOSPHOMOLYBDENUM ASSAY: 
S.No 
Concentration 
(µg/ml) 
% Inhibition of 
Std 
% Inhibition  
of  Test 
1 200 34.83 34.83 
2 400 45.28 45.28 
3 600 49.56 49.56 
4 800 63.84 63.84 
5 1000 73.41 73.41 
6 1200 84.2 84.2 
 IC 50 value 567.41 µg/ml 567.41 µg/ml 
 
Table: 5   
 
 
Fig:11 Graphical representation of  Phosphomolybdenum Assay. 
IC 50 Value of  Test (596.54µg/ml) was closed related to  standard value (567.41 µg/ml). 
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In vivo method  
Rats injected with serotonin alone developed macroscopic skin changes at the 
injection sites. The serotonin injections induced  loose stools, dyspnea, drowsiness for 
several hours after injection in all animals at first week. 
The signs of the serotonin injections were pronounced in the first four weeks 
of the study. It also caused  hyperactivity and aggressive behaviour in serotonin 
treated animals. Their  cardiac profile was evaluate by ECG and Echocardiography.  
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 BODY WEIGHT : 
GROUPS BEFORE 
TREATMENT (gm) 
AFTER TREATMENT 
  (gm) 
 GROUP  I 128.33±15.53 139.2±16.79 
 GROUPII 130.33±14.33 123±5.65a 
GROUP III 132.83±10.36 136±4.6 b 
 GROUP IV 129.66±9.89 134±10.08 b 
 
Table:6   
G I - Normal control  G II – Disease control  
G III Digoxin treated group G IV Ganoderma Lucidum treated  group. 
Values are expressed as mean±SD, (n=6). 
‘a’ => P  < 0.01 compared to control group.  
‘b’ =>  P  < 0.01 compared to disease group. 
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Graphical representation of  changes in body weight. 
         It was seen that the body weight decreased significantly in animals which were 
given serotonin as compared to control  group. Treatment with digoxin showed a 
significant increase in body weight .Ganoderma lucidum treated group of animals 
also showed significant increase in body weight.  
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Electrocardiography  recording in rats 
 HEART RATE: Normal heart rate (375±20). 
GROUPS AT BASELINE AFTER  3 MONTHS 
GROUP    I 366.66±12.16 383.83±13.19 
GROUP   II 368.83±6.91 250±36.05a 
GROUP  III 381.16±7.08 402±30.31b 
GROUP   IV 375.83±12.17 373±10.93b 
Table:7      
 G I - Normal control                         G II – Disease control   
G III Digoxin treated group              G IV Ganoderma Lucidum treated  group. 
 The values are expressed as mean±SD, (n=6). 
‘a’ =>  P values < 0.01 compared to control group. 
‘b’ =>  P values < 0.01 compared to disease group. 
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Fig:13  Graphical representation of changes in heart rate. 
It   was seen that the heart rate decreased significantly in animals which were 
given serotonin as compared to control  group to the end of 3 months. Treatment with 
digoxin showed a significant increase in heart rate. Ganoderma lucidum treated group 
of animals  showed no significant change  in heart rate.  
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Fig:14 
 ( GROUP I )  No abnormality detected 
 
Fig: 15 
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AV BLOCK GROUP III 
 
Fig:16 
VENTRICULAR BI GEMINA GROUP II 
 
Fig:17 
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BRADYCARDIA GROUP II 
 
Fig:17 
No Abnormality Detected GROUP III 
FIG: 18 
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SINUS TACHYCARDIA GROUP III 
 
FIG:19 
No Abnormality detected GROUP III 
Fig:20 
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ECG  REPORT : 
At baseline 
S.NO GROUP I GROUP II GROUP III GROUP IV 
1 NAD NAD NAD NAD 
2 NAD NAD NAD  NAD 
3 NAD NAD NAD  NAD 
4 NAD NAD NAD NAD 
5 NAD NAD NAD NAD 
6 NAD NAD NAD NAD 
 
Table:8 
ECG was normal at the beginning of the study in all the 4 groups. 
  
RESULTS 
Institute of Pharmacology, MMC.  Page | 61 
 
AFTER 3 MONTHS  TREATMENT : 
S NO GROUP1 GROUP 2 GROUP 3 GROUP 4 
1 NAD VENTRICULAR BI GEMINA 
SINUS TACHY 
CARDIA NAD 
2 NAD BRADY CARDIA TACHYCARDIA NAD 
3 NAD 1
ST DEGREE AV 
BLOCK 
NORMAL 
SINUS 
RHYTHM 
REDUCED QRS 
COMPLEX 
AMPLITUDE 
4 NAD BRADYCARDIA NAD REDUCED R AMPLITUDE 
5 NAD BRADYCARDIA NAD NAD 
6 NAD BRADYCARDIA NAD NAD 
 
Table:9 
G I - Normal control                    G II – Disease control  
 G III Digoxin treated group        G IV Ganoderma lucidum group 
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IN GROUP I  - Normal. 
IN GROUP II -  Bradycardia was present in four (66.6%) rats,  
                            VBG waspresent in one (16.6%)  rat, 
                             1ST degree  AV Block was found in one (16.6%) rat. 
IN GROUP III -  (50%) of rats (three)  did not show any abnormality.   
                             Tachycardia was present in two (33.3%) rats,  
                              Normal sinus rhythm in one (16.6%)  rat. 
IN GROUP IV -   (66.6%) of rats did not show pathological change 
                               Reduced QRS complex  amplitude was shown  in one (16.6%)  rat  
                               Reduced R amplitude  was present in one (16.6%)  rat. 
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ECHOCARDIOGRAM REPORT 
 
S.No. Group I Group II Group III Group IV 
1 NAD Aortic 
Regurgitation 
Mitral 
regurgitation 
NAD 
2 NAD Mitral 
Regurgitation 
Aortic 
Regurgitation 
NAD 
3 NAD Tricuspid 
Regurgitation 
NAD NAD 
4 NAD Mitral 
Regurgitation 
NAD NAD 
5 NAD Aortic 
Regurgitation 
NAD NAD 
6 NAD Mitral 
Regurgitation 
NAD NAD 
 
Table: 10 
In GROUP I -  No valvular abnormality was noted. 
In GROUP II - Aortic regurgitation was present in two (33.3%) rats, 
                     Mitral regurgitation was present in three (50%)of rats, 
                      Tricuspid regurgitation was found in one (16.6%) rat. 
In GROUP III - Aortic regurgitation was present in one (16.6%) rat,  
                      Mitral regurgitation was present in (16.6%) of rats, 
                      (66.6%) of rats did not show pathological changes. 
In GROUP IV -  No valvular abnormality was found. 
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GROUP I 
 
Fig:23 Echocardiographic examination did not show any pathological 
changes in control group. 
 GROUP IV 
 
Fig:24  NORMAL STUDY 
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GROUP II : 
 
Fig:25 AORTIC VALVE REGURGITATION 
 
GROUP II 
 
Fig:26  MITRAL VALVE REGURGITATION 
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ORGANS WEIGHT: 
 Heart weight 
   Liver weight                  
GROUP HEART WEIGHT (gms) LIVER WEIGHT 
(gms) 
GROUP 1 0.7±0.025 4.89±0.13 
GROUP  2 0.86±0.029a 6.2±0.2a 
GROUP  3 0.77±0.016b 5.42±0.24b 
GROUP 4 0.73±0.025b 5.15±0.14b 
 
Table:11 
 G I - Normal control                   G II - Disease control 
 G II - Digoxin treated group         G IV - Ganoderma lucidum treated group 
 Values are expressed as mean±SD, (n=6).  
‘a’ =>  P  < 0.01 compared to control group. 
‘b’ =>  P  < 0.01 compared to disease group. 
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 ORGAN WEIGHT:     
                                                                                                                                         
    Fig:20 Graphical representation of organ weight 
        It was seen that the organ weight increased significantly in animals which were 
given serotonin as compared to normal group. Treatment with digoxin showed a 
significant decrease in organ weight. Ganoderma lucidum treated group   showed 
significant decrease in organ  weight. 
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LEFT VENTRICULAR WALL THICKNESS 
 
GROUPS LEFT VENTRICULAR WIDTH (µm) 
GROUP  I 0.26±0.07 
GROUP  II 0.5±0.06a 
GROUP III 0.33±0.08b 
GROUP  IV 0.31±0.07b 
 
Tab:12, The values are expressed a mean ± SD, (n=6). 
G I - Normal control                   G II–Disease control 
 G II–Digoxin treated group         G IV - Ganoderma lucidum treated group 
 
‘a’ =>  P values < 0.01 compared to control group. 
‘b’ =>  P values < 0.01 compared to disease group. 
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Fig:27  Graphical representation of left ventricular thickness. 
It  was seen that the left ventricular wall thickness increased significantly in 
animals which were given serotonin as compared to control group. Treatment with 
digoxin showed a significant decrease in left ventricular wall thickness. Ganoderma 
lucidum treated group  also showed significant decrease in  the left ventricular wall 
thickness. 
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HEART  VALVE THICKNESS MEASUREMENT : 
 
Groups 
AORTIC 
 VALVE(µm) 
MITRAL 
VALVE (µm) 
PULMONARY 
VALVE   (µm) 
TRICUSPID 
VALVE   (µm) 
I 0.0433±0.01 0.11±0.005 0.053±0.01 0.0310.004 
II 0.0766±0.01a 0.13±0.008a 0.085±0.01a 0.0560.005a 
III 0.0516±0.02b 0.14±0.011b 0.063±0.01b 0.038±0.007b 
IV 0.0466±0.01b 0.135±0.008b 0.05±0.01b 0.041±0.004b 
Tab:14  The values are expressed a mean ±SD.  
‘a’ =>  P values < 0.01 compared to control group. 
‘b’ =>  P values < 0.01 compared to disease group. 
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Fig:28  Graphical representation of valve thickness. 
It  was seen that the heart valve thickness increased significantly in animals which 
were given serotonin as compared to control group. Treatment with digoxin showed a 
significant decrease in heart valve thickness. Ganoderma lucidum treated group  
showed significant decrease in the heart valve thickness. 
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HISTOPATHOLOGY OF HEART: 
 
 Fig : 29  GROUP I Fig : 30  GROUP II 
 
   
 Fig 31 : GROUP III Fig 32 : GROUP IV 
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DISCUSSION: 
  Carcinoid heart disease occurs in over 65% of patients with the carcinoid 
syndrome and is characterized by  thickening of cardiac valves, leading to heart 
failure. Serotonin plays a major role in the development of carcinoid heart disease32. 
Serotonin induces oxidative stress in human heart by means of increased reactive 
oxygen species especially superoxide (O2.).  
ROS appears to participate in serotonin induced mitogenesis in carcinoid heart 
disease.  Antioxidants have been found to prevent the mitogenic effects of serotonin28.  
Ganoderma lucidum is a traditional Chinese medicine, which  
consists of  triterpenes called ganoderic acids, polysaccharides,  mannitol, 
canthaxanthin, lanostan and alkaloids. Sterols isolated from the mushroom 
include,  ganoderol, ganoderenic acid20.  
It has been known to have numerous pharmacological effects including 
immune modulating, anti-inflammatory, anti cancer , anti diabetic  effect. It inhibits 
mitogen protein kinase enzyme, increases anti- oxidative enzyme activity and exhibits 
direct free radical scavenging activity. Reishi mushroom prevents the cardiotoxicity 
by its antioxidant effect. Hence this study was undertaken to evaluate the effect of   
Ganoderma lucidum on inhibiting serotonin induced carcinoid heart disease by its 
antioxidant property16,19. 
In vitro antioxidant activity was carried out Super oxide radical scavenging 
assay method, Hydroxyl radical scavenging assay method, Nitric oxide method and 
Phosphomolybdenum assay method. It was observed that as the concentration 
increases, the % scavenging also  increases linearly for ganoderma lucidum and 
standard preparation. 
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In case of  super oxide free radical scavenging assay method, the  IC50 value 
(714.36µg/ml) of Ganoderma lucidum  was almost equal  to standard 
value(691.04µg/ml) which indicates Ganoderma lucidum has potent antioxidant 
activity. 
 In  Hydroxyl radical scavenging assay method, IC50 value of red reishi 
mushroom (687.45µg/ml) was showing only much lesser  difference on comparison 
with the standard value (679.04µg/ml). 
IC 50 values (496.51µg/ml),(596.54 µg/ml) of reishi closely related to 
standard values       (459.23 µg/ml) and (537.41 µg/ml) respectively by nitric oxide 
scavenging method Phosphomolybdenum assay method.  It was found   that red reishi 
mushroom   displayed    antioxidant  potential aganist reactive oxygen species.                  
In  in vivo study, serotonin alone  treated group of rats showed significant 
reduction in the body weight which was prevented by the Ganoderma lucidum and 
this correlates with the study done by Bjorn.I.Gustafsson  et al (2005)30  
At baseline ECG were normal in all groups. After  3 months of serotonin 
induction, serotonin alone treated  rats  showed bradycardia (66.6%), ventricular bi 
gemina (16.6%) and 1st  degree AV block (16.6%). Heart rate reduced significantly 
(P<0.01) which was found to be reversed in  the  Reishi mushroom treated group upto 
(66.6%) where as the Digoxin treated group showed normal heart rate in 66.6% and 
sinus tachycardia in 16.6%. 
In Echocardiography serotonin alone treated animals, showed Mitral 
regurgitation(50%), Aortic regurgitation(33.3%) and Tricuspid regurgitation(16.6%) 
and this finding correlated with the study done by Bjorn.I.Gustafsson et al (2005).30 
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Among the rats treated with Digoxin no valvular abnormality was found in 66.6% 
where as  (16.6%) showed mitral regurgitation and 16.6% showed aortic 
regurgitation. 
No valvular abnormality was found in Ganoderma lucidum treated group 
depicting its excellent protective  effect in preventing serotonin induced valvular 
changes. 
Ganoderma lucidum showed significant decrease in  organ mass  
induced by  serotonin. It is proved that this mushroom may  have the anti proliferative 
property on cells which was in accordance with the study done by Hauso,  
Loennechen JP et al (2007)29 . 
Macroscopically, left ventricular  wall thickness is more in serotonin alone 
treated group (0.5±0.06µm) compared to  mushroom treated group(0.31±0.01µm) 
which correlates with the study done by Steven Droogmans et al(2007)31. 
In valvular pathology,  the thickness of aortic (0.0766±0.01µm), pulmonary 
(0.085± 0.01µm) ,tricuspid (0.056± 0.005µm), mitral valves (0.13± 0.008µm)  in 
serotonin alone treated group was  significantly increased  due to the valvular lesion 
which was decreased by ganoderma lucidum treated group. More over regurgitant 
aortic, mitral and tricuspid  valves were thicker than non regurgitant valves. 
In histopathological examination, the serotonin treated animals were found to 
have increased cellularity of myofibrobasts in collagenous matrix with extensive 
hypertrophy of cardiac smooth muscle. Aortic valves showed myxoid degeneration.  
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Ganoderma lucidum treated group showed normal histology of  cardiac 
muscle fiber sections studied from aortic, mitral, tricuspid and pulmonary valves in 
84% and   mild hypertrophy of  cardiac smooth muscles in 16.6%. 
Ganoderma lucidum treated rats exhibited a  reduction of incidence of aortic, 
tricuspid and mitral regurgitation on echocardiography and normal aortic, tricuspid 
and mitral thickness in histopathological evaluation which correlates with  the study 
done by Steven Droogmans et al(2007)31. 
In this study Ganoderma lucidum had a preventive effect against the 
development of serotonin induced carcinoid heart disease in rat  model. 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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IX. CONCLUSION: 
 The antioxidant property of ganoderma lucidum was confirmed by in vitro 
studies namely  Super oxide radical scavenging assay method, Hydroxyl 
radical scavenging assay method,  Nitric oxide method,  Phosphomolybdenum 
assay method. 
 
 Ganoderma lucidum inhibited effects of serotonin induced carcinoid heart 
disease probably by reducing oxidative damage by scavenging free radicals in 
the cells. 
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